Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

PURPOSE: Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits e...

Descripción completa

Detalles Bibliográficos
Autores principales: Wardell, Suzanne E., Yllanes, Alexander P., Chao, Christina A., Bae, Yeeun, Andreano, Kaitlyn J., Desautels, Taylor K., Heetderks, Kendall A., Blitzer, Jeremy T., Norris, John D., McDonnell, Donald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985185/
https://www.ncbi.nlm.nih.gov/pubmed/31562570
http://dx.doi.org/10.1007/s10549-019-05454-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985185/
https://www.ncbi.nlm.nih.gov/pubmed/31562570
http://dx.doi.org/10.1007/s10549-019-05454-y

Ejemplares similares